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Background: This study reports the reliability and validity of a questionnaire designed to measure the time from
detection of a breast cancer to arrival at a cancer hospital, as well as the factors that are associated with delay.
Methods: The proposed questionnaire measures dates for estimation of the patient, provider and total intervals
from detection to treatment, as well as factors that could be related to delays: means of problem identification
(self-discovery or screening), the patients’ initial interpretations of symptoms, patients’ perceptions of delay, reasons
for delay in initial seeking of medical care, barriers perceived to have caused provider delay, prior utilisation of
health services, use of alternative medicine, cancer-screening knowledge and practices, and aspects of the social
network of support for medical attention. The questionnaire was assembled with consideration for previous
research results from a review of the literature and qualitative interviews of patients with breast cancer symptoms.
It was tested for face validity, content validity, reliability, internal consistency, convergent and divergent validity,
sensitivity and specificity in a series of 4 tests with 602 patients.
Results: The instrument showed good face and content validity. It allowed discrimination of patients with different types
and degrees of delay, had quite good reliability for the time intervals (with no significant mean differences between the
two measurements), and fairly good internal consistency of the item dimensions (with Cronbach’s alpha values for each
dimension between 0.42 and 0.85). Finally, sensitivity and specificity were 74.68% and 48.81%, respectively.
Conclusions: To the best of our knowledge, this is the first published report of the development and validation of a
questionnaire for estimation of breast cancer delay and its correlated factors. It is a valid, reliable and sensitive instrument.
Keywords: Breast cancer, Delayed medical care, Questionnaire, Validity, ReliabilityBackground
Breast cancer is the most common cancer in women
and the main cause of cancer-related deaths worldwide,
causing approximately 2-million new cases and 500,000
deaths in 2008 [1]. It is also the main cause of cancer-
related deaths among women in Mexico, with close to
14,000 new cases and 5,000 deaths per year [1].
In Mexico, as in other developing countries, breast can-
cer survival rates are much lower than in developed coun-
tries, mainly because cancer is diagnosed in later stages.
For instance, in the United States, 60% of breast cancer
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distribution, and reproduction in any medium98% [2], whereas in Mexico less than 10% of patients are
diagnosed in these early stages and 47% in the most
advanced stages (III and IV) [3,4]. The main reasons for
presentation of breast cancer patients in advanced stages
in Mexico could be related to the very low participation of
women in breast cancer screening tests [5], delayed help-
seeking for breast cancer symptoms and barriers to acces-
sing health care services [6].
Breast cancer total delay is defined in the literature as a
span of more than three months between the discovery of
symptoms by the patient and the beginning of definitive
cancer treatment [7-9]. Traditionally, it has been classified
in two types: patient and provider delay. Cut-points to de-
fine these intervals vary across studies, but the majority of
studies have considered patient delay to be more than
three months between the discovery of symptoms and the
first medical consultation [7,10-12]. In turn, provider delayCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Unger-Saldaña et al. BMC Cancer 2012, 12:626 Page 2 of 13
http://www.biomedcentral.com/1471-2407/12/626takes place between the first medical consultation and the
beginning of definitive treatment, and the most accepted
threshold is one month, although this cut-point varies
across studies [13-17].
Although breast cancer treatment delay has been stud-
ied by multiple authors for years, there is no validated
instrument to measure time intervals and correlated fac-
tors. Several instruments to estimate the likelihood of
delay in seeking medical attention if a cancer symptom
were to present have been validated in asymptomatic
patients [18,19], but no studies have assessed delay
among breast cancer patients. Some breast cancer delay
studies refer to questionnaires based on previous study
results or describe the results of pilot studies, but no val-
idity and reliability measures are specified [20-22]. We
found only one study in which the reliability and validity
of self-reported symptoms and dates of diagnostic tests
was measured, but this study surveyed patients with
colon cancer [23], which is characterised by a completely
different set of symptoms, natural history and illness be-
haviour compared to breast cancer [24-27]. Nonetheless,
the authors found that self-reported symptoms, tests
and dates were in general reliable but not necessarily
valid [23].
This dearth of validated instruments that measure
delay is most likely a result of the difficulties inherent in
establishing the validity of time intervals for medical
care for any disease [28]. These intervals are estimated
based on the date of symptom discovery, the date of ini-
tial medical consultation and the date of beginning of
treatment. The most problematic dates to obtain reliably
are those given by the patient, as there may be recall in-
accuracy [29] and response bias due to concerns about
social desirability [30]. Nevertheless, it has been shown
that patients commonly recall the precise time when
they first discovered their symptoms [12,23,31].
Due to the known association between delay, advanced
clinical stages of breast cancer and survival [32], it is im-
portant to quantify the degree of delay and its correlated
factors so that targeted interventions to reduce delay can
be designed. Such interventions are especially important
in developing countries where the majority of patients
are diagnosed in advanced stages, as in Mexico [33].
In this paper, we report the development and valid-
ation of a questionnaire designed to a) measure the time
from detection of a possible breast cancer (through either
patient symptoms or abnormal screening findings) to ar-
rival at a cancer hospital and b) identify factors corre-
lated with the delayed beginning of medical treatment.
Methods
Study design
The study protocol was approved by the scientific and
ethics review boards of the Mexican National University(registry number 24–2007) and the National Cancer
Institute (registry 05048TMI). The results here pre-
sented are part of a larger study that aims to quantify
time intervals from the detection of a possible breast
cancer to the beginning of cancer treatment and identify
the main factors predicting prolongation of these inter-
vals. This paper reports the development and validation
(using standard test-construction methods) of an instru-
ment to assess time from detection of breast cancer to
arrival at a cancer hospital and possible associated fac-
tors with delayed beginning of treatment [28,34]. After
the first draft of the questionnaire was written, it was
tested for psychometric properties and refined in a set of
4 cross-sectional tests of different patients. The con-
struction and validation of the questionnaire are sche-
matised in Figure 1.
Construction of the questionnaire
The questionnaire was built to assess time from the first
identification of a breast problem that could be cancer
(either through screening practices or symptoms discov-
ered by the patient) to arrival at a cancer hospital, and
possible associated factors with delayed beginning of
treatment. The questionnaire was assembled with con-
sideration for previous research results from a review of
the literature and qualitative interviews of patients with
breast cancer symptoms. Details of these previous study
phases are published elsewhere [9,35]. Nevertheless, it is
important to emphasise that the definitions and classifi-
cations of the time intervals, as well as those of the cor-
related factors and the methods used for their study,
were critically assessed and considered in the construc-
tion of the instrument.
Furthermore, the first draft of the questionnaire
included items reflecting the most common themes in
the qualitative patient interviews. The instruments’ ques-
tions and response categories were phrased in simple
terms and in accordance with the words used by the
patients in the qualitative interviews. The items were
then revised and improved after evaluation by experts in
the design of questionnaires and a multidisciplinary
team of advisors: a sociologist, a clinical epidemiologist
and anthropologist, an oncologist, an epidemiologist and
a statistician. Finally, they were tested for comprehensi-
bility by the participants in the first pilot study.
The questionnaire was designed for application through
face-to-face interviews due to the difficulties associated
with self-administered research instruments in Mexico
among people with little formal education [36,37], like our
study participants.
The conceptual and operational definitions of the time
intervals agree with the majority of studies of breast
cancer delay and recent recommendations of a consen-
sus [38]. Total interval was defined as the time from
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Figure 1 Stages in the production of the breast cancer delay questionnaire. This schema summarizes the stages of construction and
validation of the questionnaire.
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or screening) to the beginning of cancer treatment; pa-
tient interval was defined as the time from identification
of the problem to the first medical consultation; and
provider interval was defined as the time from the first
presentation (first medical consultation) to the beginning
of cancer treatment. Date of symptom discovery and date
of presentation were both obtained from the patients
through the questionnaire, whereas the dates of begin-
ning of treatment were obtained from their hospital
charts.Participants
The patients included in this study were women who
were referred to the Breast Tumours Department of the
Mexican National Cancer Institute (INCAN) with a
probable breast cancer diagnosis. INCAN is a referral
hospital that offers specialised cancer care at low costs
for uninsured patients, most of whom are unemployed
or informally employed.
Patients were excluded if they had received previous
cancer treatment for the current breast cancer, if they
had a personal history of cancer, if they were unable toparticipate in the interview (because of impaired hear-
ing, inability to communicate in Spanish, or mental dis-
ability), or if they had a history of a benign breast
condition that had been under medical surveillance. This
last exclusion criterion was considered because the pro-
file of women with benign breast disease has been
shown to differ significantly from that of women with
breast cancer [9]. Additionally, completed questionnaires
were excluded from analysis if the patient did not recall
one or more of the relevant dates.Interviews
In the first pilot study, KUS conducted all of the inter-
views. From the second pilot study onwards, the inter-
viewers were psychologists who were trained by KUS to
standardise the interviewing process. Training consisted
in a first theoretical module, a second phase of super-
vised practice of interviews with individuals that simu-
lated fictitious patient stories, and a third phase where
the interviewers administered the questionnaire to breast
cancer patients in the presence of KUS. The patients
who were interviewed in the training stage were not
included in the final analysis.
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partment were invited to participate while they were
waiting for their first consultation with the breast spe-
cialist. The interviewer identified herself and asked the
patient for verbal consent to ask her three questions (the
exclusion criteria). If the patient was eligible for the
study, she was then invited into a private room with the
person who accompanied her to the hospital. No monet-
ary incentives were given. The patient was given a writ-
ten description of the study objectives and what her
participation would consist of, including her rights to
not participate. The trained interviewer read this form
with the patient and relative and then offered to clarify
any issues that remained ambiguous. Finally, if she was
willing to participate, she was asked to sign an informed
consent form, and her relative was asked to sign as a
witness. After informed consent was obtained, the
patient’s relative was asked to wait for the patient out-
side so that the interview could be done in private.
All dates were retrieved in the form of day, month and
year with the aid of calendars and in relation to events
that occurred during the patient’s help-seeking trajectory,
including national holidays, significant news and personal
events such as the participant’s birthday. Calendars were
printed out, and as part of the standardised interview
process, the interviewers gave each participant a calendar
and asked her to recall the relevant dates as precisely as
she could. This procedure enhanced recall, as the partici-
pant could deduce the date of a health event from the cal-
endar by locating it in relation to other significant dates.
For participants who had lesions detected by screen-
ing, the date of problem identification was considered to
be the date of first contact with a medical service; thus,
the patient interval was 0 days. When the patient did
not remember the exact date, she was asked to remem-
ber whether it was in the beginning, middle or end of
the month. The beginning of the month was coded as
day 5, the middle of the month as day 15, and the end of
the month as day 25. If she could not be more precise,
her answer was coded as day 15 (middle of the month).
Some patients with several years of delay could remem-
ber only the year. These patients were asked to remem-
ber if the date was early in the year, mid-year or late in
the year. These answers were coded as follows: “begin-
ning of the year”, 15 February; “middle of the year”, 15
June; and “end of the year”, 15 November. If she remem-
bered only the year, the answer was coded as “middle of
the year”.
Participants were not directed in any way by the inter-
viewers to obtain an answer. Part of the standardisation
consisted in reading each question to the patient two
times word-for-word if she did not understand the first
time. If the participant still did not understand after the
second time the question was asked, then theinterviewers paraphrased the question. Finally, if no re-
sponse was elicited after the third attempt, the inter-
viewers marked that question as unanswered and went
on to ask the next item.Review of patient files
To quantify the total delay and provider intervals, the
dates required are that of problem identification, first
medical consultation and beginning of treatment. The
instrument was designed to assess only the first two,
since the patients were interviewed before they began
cancer treatment. Therefore, the participants’ medical
files were reviewed six months after the interview to ob-
tain the date that the first cancer treatment was begun
and the clinical stage of the cancer. The beginning of
cancer treatment was considered as the date that the
first oncologic treatment was begun, whether it was sur-
gery, chemotherapy, radiotherapy, hormonal therapy or
antibody therapy.Procedures and measures
Sensibility analysis
Sensibility was appraised in a qualitative manner by the
researchers in terms of what the instrument contains
and what it does, as recommended by Feinstein [28].
The following topics were analysed: a) comprehensibility,
b) replicability, c) suitability of scale, d) face validity, e)
content validity, f ) ease of usage and g) patient accept-
ance. This assessment was performed continuously
throughout the different stages of the study. Items that
were irrelevant or duplicated in early versions of the
questionnaire were eliminated. Those that were found
by respondents to be ambiguous or difficult to under-
stand were rewritten, and some new categories were
incorporated when an answer that had not been consid-
ered in the previous version was given by more than
10% of the interviewees. Finally, the item order was
changed after the first and second pre-test studies to
make the interview more fluent.Reliability
External consistency or reliability was estimated with a
test-retest analysis of 30 patients who participated in the
second pre-test and to whom the same instrument was
applied twice within a 3-month interval. Appointments
for the second interview with these participants were
scheduled by telephone. The second interview was
arranged at a date and time that was convenient for the
patient and on the same day as one of her medical
appointments so that she did not have to come to the
hospital only for the interview.
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Different timings for the interviews were tested to maxi-
mise patient cooperation and minimise interference with
the usual institutional procedures. This was conducted
in a qualitative manner by the researchers. Furthermore,
the proportion of patients that reported dates with preci-
sion was compared for the participants in the test-retest.
Validity
Criterion validity was not assessed, as there is no gold-
standard instrument to measure delay or the factors
associated with it. Construct validity was evaluated for each
questionnaire dimension by estimating internal consistency
and convergent and divergent validity [28,39].
Item scoring
Responses within each item were assigned a value
according to their bivariate association with the different
time intervals (total, patient and provider). More points
were given to the response categories associated with
longer intervals, and fewer points were given to those
associated with shorter intervals. For each item the re-
sponse category associated negatively with delay was
given a value of 0, the category with the highest positive
association with delay was given the highest value, and
the remaining response categories were given values in
between accordingly. The assigned value for each item’s
response categories depends on the number of response
categories. If there were four response categories, the
lowest value would be 0 and the highest 3, whereas if
there were two categories the values would range only
from 0 to 1. For example, the item “means of problem
identification” had a score of 0 when the problem was
identified through screening and 1 when it was identified
through patient symptoms. To determine a score for
each dimension of the questionnaire, the component
item scores for each patient were summed. Finally, to
determine the total questionnaire score, scores for all
dimensions were added up.
Sensitivity and specificity
ROC curves were estimated for the total questionnaire
scores in relation to total, patient and provider delays.
As there is no gold standard, the total questionnaire
score was dichotomised using the median as the cut-off
point [28,39]. The intervals were also dichotomised with
the following cut-off values: total delay was recorded
when the total interval was equal to or greater than
180 days; and patient or provider delay was recorded
when the patient or provider interval was 90 days or
more. We decided to use cut-off points that are much
longer than the most widely accepted thresholds in the
literature because 97% of the women in our sample had
total intervals greater than 90 days.Final item selection
Bivariate analysis of each of the questionnaire items and
the three time intervals was performed to identify the
factors most likely to predict delays. Those items that
showed the highest correlations were kept for the final
version of the questionnaire. Those that were not statis-
tically significant but hold theoretical relevance were
also kept in the final version of the questionnaire. The
purpose of this study was to assess the instruments’ valid-
ity and reliability, not draw conclusions regarding the rele-
vance of each item to delay. In the next phase of the
study, a multivariate analysis of a larger, multi-centre sam-
ple will allow determination of each item’s relevance and
further refinement of the instrument.Statistical analysis
Sample sizes were based on the quality criteria recom-
mended by Terwee et al., who suggested a minimum of 50
patients for assessing construct validity and a minimum of
100 patients for assessing internal consistency [40].
Descriptive statistics were estimated to measure the par-
ticipants’ sociodemographic characteristics, final diagnoses
and clinical stages, as well as for the total, patient and pro-
vider intervals. The quantitative variables included mean,
median, standard deviation and interquartile range; cat-
egorical variables included frequency and percentage.
To reduce the questionnaire, a correlation matrix of
variables and a principal component analysis of each di-
mension were carried out. For pairs of variables with
correlation coefficients higher than 0.70, we selected the
one that explained the greatest variation according to
the principal component analysis.
To evaluate test-retest reliability, a t-test for related
samples was performed to compare mean differences in
interval lengths between the two measurements. A cor-
relation matrix was estimated for the remaining variables
to compare responses between the first and second
questionnaire applications for each individual. Further-
more, the total score obtained by each patient on the
first and second application of the questionnaire was
compared for each dimension.
Internal consistency was assessed through estimation
of Cronbach’s alphas for each questionnaire dimension,
as recommended by Terwee and collaborators [40].
Alphas equal to or greater than 0.40 (p < 0.05) were con-
sidered acceptable [34,41]. Convergent validity was
assessed by estimating Spearman correlation coefficients
for items comprising each domain, and divergent validity
across items of different domains.
To select the final items in the instrument, bivariate
associations were estimated between each questionnaire
item and each of the three intervals (total, patient and
provider) through Likelihood Ratio (LR) coefficients and
Table 1 Questionnaire dimensions and items
1. Means of problem identification (self discovery or screening)
2. First symptom identified by the patient
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ficients greater than 10 (p < 0.05) and significant ORs
(p < 0.05) were considered to have statistical relevance.3. Patient initial interpretations of symptoms
Perceived seriousness Initial worry
Initial interpretation of cancer
4. Breast cancer symptoms present at arrival to the cancer hospital
Lymphadenopathies Breast ulcer
Breast pain Breast pruritus
Arm pain Breast enlargement
Paresthesias of breast and/or
ipsilateral arm
Form changes of the breast
Breast skin changes Nipple discharge
5. Most worrisome symptom for the patient
6. Patient's reason for seeking medical care (appearance of
symptoms/persistence of symptoms/worsening of symptoms)
7. Patient's perception of delay
Perception of patient delay Perception of provider delay




Didn't know where to seek
care
Fear
Lack of financial resources Embarrassment
Difficulty to miss work Taking care of young children, older
or ill relatives
9. Patient's perceived barriers to have caused provider delay
Lack of information of health
services
Lack of financial resources
Fear Difficulty to miss work
Perceived errors in diagnosis
of first doctors consulted
Perceived long waiting times for
medical appointments
Had to take care of
youngsters, elders or ill relatives
Had to borrow money to get medical
care
Financing source for payment
of health care
10. Health service utilizationResults
Description of the instrument: the breast cancer delay
questionnaire
The final questionnaire is composed of two independent
modules containing 68 items. These items mainly include
categorical answers, Likert scales and several open-ended
questions. One module assesses dates to estimate the
intervals in which delay can occur. The other measures
different factors predisposing to delay. The two modules
are intertwined in the questionnaire to facilitate its appli-
cation. In the first pilot study, we tested the two modules
separately and found that it was more difficult to elicit
responses. On the one hand, it was harder for the patient
to recall the dates of symptom discovery and first medical
consultation without having discussed how they discov-
ered the first symptom or where they sought medical at-
tention for their health problem. On the other hand,
questions about reasons for having delayed care or bar-
riers to accessing care required respondents to think about
dates and how much time had passed.
The combined application of this instrument and a revi-
sion of patients’ clinical files to assess the dates of diagno-
sis confirmation and the beginning of cancer treatment
allow the estimation of total, patient and provider inter-
vals, as well as of the subintervals that compose the pro-
vider intervals: diagnosis and treatment intervals. The
instrument is organised in 8 questionnaire sections that
encompass 16 dimensions. Table 1 shows the question-
naire dimensions and the included items. The question-
naire in Spanish, is available for free in the BMC Cancer
webpage (Additional file 1). Although the attached version
of the questionnaire does not include sociodemographic
items, it is certainly recommended that these are added in
accordance to the context where it will be administered.First health service used
(public, private, other)
Breast ultrasound requested by first
doctor consulted
Number of different health
services consulted
Biopsy requested by first consulted
doctor
Diagnostic impression of the
first doctor consulted
Health service of referral to hospital
Mammogram requested by
the first consulted doctor
Biopsy done previous to arrival at
hospital
11. Social network support for seeking medical attention
Instrumental support Sex of person of most support




Sex of social network membersPre-test 1. Face and content validity (Stage 2)
The first version of the questionnaire, which comprised
129 items, was applied to 43 patients who came to the
Breast Clinic of INCAN for the first time between January
and May 2008 with a probable breast cancer diagnosis
(Figure 1). Patient demographic, disease and delay data
are summarised in Table 2. The aim of this stage was to
evaluate the instrument’s sensibility [28]. The most im-
portant modifications to the questionnaire that arose from
this stage were 1) rearrangement of the sequence of items
to make the interview more fluent, 2) rewording of ques-
tions, 3) addition of response categories, and 4) elimin-
ation of items that showed no variation.
Table 1 Questionnaire dimensions and items (Continued)




Sex of first person who she told
Kinship with person of most
support
Number of women older than 15
living at same household
12. Time between identification of the problem and the first time
to talk to someone about it
13. Use of alternative medicine
14. Cancer-related knowledge
Knowledge of a person with
cancer
Has heard about mammograms
Knowledge of mammograms'
utility
Knowledge of recommended age for
first screening mammogram
15. Cancer screening practices




Breast Self Examination practice
16. Dates
Symptom discovery First medical consultation
Unger-Saldaña et al. BMC Cancer 2012, 12:626 Page 7 of 13
http://www.biomedcentral.com/1471-2407/12/626Pre-test 2. Item reduction, reliability and date accuracy
(Stage 3)
The second draft of the questionnaire, with 112 items,
was applied to 50 patients with probable breast cancer
on their arrival at INCAN between June 15 and July 8,
2009. Patient demographic and disease information is
shown in Table 2. After the correlation matrix of vari-
ables and principal component analysis for each ques-
tionnaire dimension were done (data not shown), the
third draft of the questionnaire was reduced to 94 items.
Reliability
A test-retest was performed for 53 of the 66 final items
measuring factors correlated with delay and the delay inter-
vals. The t-test results comparing the means of the interval
lengths are presented in Table 3. There were no significant
mean differences between the two measurements.
Questionnaire items showed quite good external
consistency in general. Table 4 presents descriptive sta-
tistics for the scores obtained from each questionnaire
dimension in Test 1 and Test 2. Correlations between
pairs of measurements for individual items are not
shown, but in summary, the results were as follows: 16
items had excellent consistency, with correlation coeffi-
cients equal to or greater than 0.75 (p<0.05); 32 items
had moderate-to-good consistency, with correlation
coefficients between 0.4 and 0.75 (p<0.05); and 18 had
poor consistency, with coefficients less than 0.4, al-
though as is argued in the discussion section, this find-
ing could be an effect of the passage of time.Best time for the interviews
After testing different moments for performing the
interviews, we determined that the best moment for the
interview to take place was before the patient was seen
by the breast specialist for the first time after her arrival
to INCAN. At this moment, patient cooperation and re-
call of dates and events prior to her arrival at INCAN
were maximised and interference with institutional pro-
cedures was minimised. While 66.7% (20/30) were able
to give a precise date for problem identification in the
first interview, in the second interview (three months
later), only 36.7% (11/30) were able to recall a precise
date. Similarly, 83% (25/30) were able to remember the
precise date of the first medical consultation in the first
interview, and only 56.7% (17/30) were able to do so in
the second interview.
Pre-test 3. Internal consistency (Stage 4)
125/167 new patients that arrived for the first time at
the Breast Tumors Department of INCAN between July
20th and October 5th of 2009, were interviewed
(Table 2). The questionnaire dimensions showed good
internal consistency in this sample, with Cronbach’s
alphas in the range of 0.51 to 0.90 (data not shown).
Final test. Item selection and validity assessment (Stage 5)
Five hundred and sixteen women who arrived at the
Breast Clinic of INCAN between October 2009 and July
2010 were invited to participate in test 4. The sociode-
mographic characteristics of the 384 participants are
summarised in Table 2.
The following analyses were performed with patient
samples from tests 3 and 4, for a total sample size of 509
patients. Figure 2 summarises the inclusion, exclusion
and elimination criteria.
Final item selection
The majority of the final items that were selected had sig-
nificantly high LR correlation coefficients and bivariate lo-
gistic regression ORs. Among the items with the highest
associations (LR>10 and/or OR>2) with total delay were
perceived medical errors (LR=26.27, p=0.000; OR=4.02,
95% CI: 2.26-7.14; p=0.000), difficulty missing work
(LR=11.96, p=0.001; OR=3.39, 95% CI:1.59-7.23; p=0.002,),
long waiting times for medical appointments (LR=11.96,
p=0.001; OR=3.49, 95% CI:1.59-7.23; p=0.002,), having
consulted more than two different health services prior to
arrival at INCAN (LR=19.03, p=0.000; OR=2.78,, 95%
CI:1.74-4.42; p=0.000), the patient’s reason for seeking
medical help being worsening or persistence of symptoms
rather than appearance (LR=13.92, p=0.000; OR=2.61,,
95% CI:1.57-4.33; p=0.000) and the patient taking longer
than 30 days to talk to someone about her breast problem
(LR=9.57, p=0.002; OR=2.28,, 95% CI:1.32-2.90; p=0.003).
Table 2 Demographic and disease informationa
Pretest 1 Pretest 2 Pretest 3 Test
(n=43) (n=50) (n=125) (n=384)
Age (years)
Mean (SD, range) 47.51 (12.29, 27–78) 51.08 (11.96, 28–81) 50.96 (12.12, 28–86) 49.61 (12.85, 18–91)
Marital status
Married or living together 23 (54) 33 (66) 69 (55) 216 (56)
Other 20 (46) 17 (34) 56 (45) 168 (44)
School education
Analphabet 4 (9) 5 (10) 15 (12) 28 (7)
6 years or less 20 (46) 25 (50) 42 (34) 134 (35)
Between 7 and 9 years 11 (26) 13 (26) 27 (21) 92 (24)
More than 9 years 8 (19) 7 (14) 41 (33) 130 (34)
Occupation
Housewife 28 (65) 26 (52) 60 (48) 222 (58)
Informal employment NA 18 (36) 48 (38) 130 (34)
Formal employment NA 6 (12) 17 (14) 32 (8)
Monthly family income
3 minimum wages or less NA 39 (78) 89 (71) 243 (63)
More than 3 minimum wages NA 10 (20) 24 (19) 79 (25)
Did not respond NA 1 (2) 12 (10) 45 (12)
Means of problem detection
Patient self discovery 38 (88) 43 (86) 101 (81) 297 (77)
Screening CBE or mammogram 5 (12) 7 (14) 24 (19) 87 (23)
Final diagnosis
Benign disease 11 (26) 7 (14) 24 (19) 117 (30)
Cancer 31 (72) 43 (86) 98 (79) 259 (68)
Unconfirmed 1 (2) 0 3 (2) 8 (2)
Cancer stage
Stage 0 & I 1 (3) 4 (8) 12 (12) 35 (14)
Stage II 12 (39) 22 (44) 37 (38) 86 (33)
Stage III 12 (39) 12 (24) 35 (36) 90 (34)
Stage IV 5 (16) 4 (8) 14 (14) 34 (13)
Unknown 1 (3) 8 (16) 0 14 (6)
Delay intervals (days): median (IQR)
Total interval 272.50 (391.50) 255.00 (402.00) 261.00 (403.00) 234.50 (361.00)
Patient interval 30.00 (318.00) 23.00 (86.75) 14.00 (79.00) 11.00 (84.00)
Provider interval 136.50 (199.75) 135.00 (406.00) 167.00 (284.00) 141.00 (213.00)
a Values are number (%) unless specified; NA Not Available, CBE Clinical Breast Exam, IQR Interquartile Range.
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of support for medical attention were not significant.
Nevertheless, they were kept because of their theoretical
relevance.
Sensibility analysis
The instrument is comprehensible and replicable, but
we strongly recommend that people who are toadminister it receive training. The output scales have
comprehensive and mutually exclusive response categor-
ies and allow discrimination of different features. The
items have face validity, as they elicit the intended infor-
mation, and they were well accepted and generally easily
understood by both interviewers and interviewees.
Content validity was assured in the construction of the
questionnaire by including items derived from the
Table 3 Test-retest of intervals
Mean (SD) Corr. Mean difference (95% CI)
Total interval 1 305.63 (237.47) 0.72*** 62.97 (−1.74,127.68)
Total interval 2 242.67 (222.44)
Patient interval 1 83.63 (132.38) 0.70*** −27.37 (−81.37, 26.63)
Patient interval 2 111.00 (201.00)
Provider interval 1 220.40 (227.56) 0.36* 76.57 (−5.67, 158.79)
Provider interval 2 143.83 (141.55)
* p < 0.05, *** p < 0.001.
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the appropriateness of included items reviewed by a
multidisciplinary team.
The administration of the questionnaire may be time-
consuming, taking in average 40 (SD=14.6) minutes. The
instrument is usually more time-consuming to adminis-
ter to older women and to those with no or incomplete
primary school education, as these women have greater
difficulty in remembering dates and understanding some
questions. The instrument was, however, well accepted
by patients, with only 4.4% (24/540) of those invited re-
fusing to participate after the study was explained to
them (Figure 2). Patient cooperation during the inter-
view was good, and participants were usually highly
motivated. After the interview, the majority of patients
thanked the interviewer for listening to them.
The total score for the questionnaire ranged from 11 to
67 points, with a mean of 37 (SD = 11.52) points (n=509).Table 4 Test-retest dimension scores
Dimensions
Total questionnaire score
1. Means of problem identification
2. First symptom identified by the patient
3. Patient initial interpretations of symptoms
4. Breast cancer symptoms present at arrival to the cancer hospital
5. Most worrisome symptom for the patient
6. Patient’s reason for seeking medical care
7. Patient’s perception of patient delay
8. Patient’s perceived reasons for patient delay
9. Patient’s perceived barriers to have caused provider delay
10. Health service utilization
11. Social network support for medical attention
12. Time between problem identification and talking to someone
13. Use of alternative medicine
14. Cancer-related knowledge
15. Cancer screening practices
SD Standard deviation, NA Not Available.Construct validity
Internal consistency
The instrument has fairly good internal consistency, with
Cronbach’s alpha for each dimension in the range of
0.42 to 0.85 (Table 5). Although we tried to build a scale
for the items related to the social network of support, as
well as for those in the health service utilisation dimen-
sion, these items had very low Cronbach’s alpha values
and were therefore left disaggregated.
Convergent and divergent validity
The majority of items within the following dimensions
showed moderate degrees of correlation with each other:
patient’s initial interpretation of symptoms (r=0.52 – 0.72,
p=0.000), reasons for delay in initial seeking of care
(r= 0.21 – 0.64, p=0.000) and perceived barriers in the pro-
vider interval (r= 0.23 – 0.62, p=0.000). Items in the fol-
lowing dimensions correlated poorly (r ≤ 0.30): symptoms
present on arrival at the cancer hospital, social-network
support for seeking medical care, health service utilisation,
cancer-related knowledge and cancer-screening practices.
Items belonging to different dimensions in general were
not correlated or were poorly correlated (r < 0.30), except
for perception of patient delay, which was moderately cor-
related with most of the perceived reasons for patient delay
and with time between identification of the problem and
the first time talking to someone about it (r =0.35 – 0.74,
p=0.000). Additionally, perception of provider delay was
correlated with most of the perceived barriers for provider
delay (r = 0.29 – 0.69, p=0.000).Mean (SD, range)
Test 1 Test 2
30 (8.48, 12–44) 27 (8.65, 11–41)
1 (0.38, 0–1) 1 (0.41, 0–1)
1 (0.51, 0–1) 0 (0.51, 0–1)
4 (2.35, 1–8) 4 (2.31, 1–8)
2 (1.66, 0–6) 2 (1.52, 0–5)
0 (0.51, 0–1) 0 (0.49, 0–1)
1 (0.44, 0–1) 1 (0.51, 0–1)
2 (1.65, 0–3) 2 (1.21, 0–3)
4 (2.45, 0–8) 3 (2.65, 0–9)
NA NA
6 (2.27, 1–10) 5 (2.31, 1–9)
5 (0.50, 4–5) 5 (0.51, 4–5)
0 (0.41, 0–1) 0 (0.42, 0–1)
1 (0.41, 0–1) 0 (0.18, 0–1)
3 (1.11, 0–5) 3 (1.09, 1–5)
2 (1.22, 0–5) 2 (1.43, 0–5)
Figure 2 Patients’ inclusion, exclusion and elimination criteria. This diagram illustrates the process of invitation, exclusion, informed consent
and elimination of study participants of the pretest 3 and test 4.
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The results derived from a ROC curve analysis are pre-
sented in Table 6. The questionnaire score predicted
total, patient and provider delays with sensitivities of
74.68%, 66.67% and 81.17% and specificities of 48.81%,
77.70% and 20.24%, respectively. In general, it shows fair
sensitivity and poor specificity, with higher specificity for
patient delay than for provider delay.
Discussion
To the best of our knowledge, this is the first published
report of the development and validation of a question-
naire for estimation of the breast cancer total, patient
and provider intervals and the correlated factors with
delays. Due to the association between delay and prog-
nosis for breast cancer [32], it is important to quantify it




Symptom interpretation 0.77*** 0.72-0.80
Symptoms at arrival to cancer hospital 0.59*** 0.53-0.65
Reasons to delay seeking medical care 0.85*** 0.82-0.87
Perceived barriers to reach cancer hospital 0.73*** 0.69-0.77
Breast cancer knowledge 0.50*** 0.43-0.56
Cancer screening practices 0.42*** 0.33-0.49
*** p<0.001.in developing countries, where the majority of patients
are diagnosed in advanced stages, as in Mexico [33].
The instrument was developed, modified and validated
using standardised test-construction methods [28,34,40].
The results of the current study show that the instru-
ment has good face validity, comprehensibility, patient
acceptance, and content validity. It has acceptable in-
ternal consistency in most dimensions (considering the
social nature of most of the items) and very good reli-
ability for most items [34,41].
Although the two modules of the questionnaire were
intertwined to facilitate its administration for this study,
they would be easy to separate if someone wished to
measure only the time intervals in another context.
Nonetheless, we found that this intertwining of modules
facilitated the questionnaire’s administration in our
population, easing the flow of the interview.Table 6 ROC Curve results of the total questionnaire







LR+ AUC (95% CI)
Total delay 40 74.68 48.81 1.46 0.62 (0.57-0.69)
Patient delay 55 66.67 77.80 3.00 0.72 (0.61-0.84)
Provider
delay
40 81.17 20.24 1.02 0.51 (0.46-0.55)
LR+ Likelihood Ratio Positive, AUC Area under the ROC Curve, CI Confidence
Interval.
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vals. In agreement with other studies, this shows that
patients tend to recall the precise time when they first
discovered their symptoms [12,31] or at least the month
and year of this discovery [23]. Nevertheless, the pro-
vider interval did not show very good consistency.
Because the test-retest measurements were taken with a
3-month separation, the variation in the estimation of
this interval may be explained by recall bias. Apparently,
memory was more affected in our participants in rela-
tion to the first medical consultation than in relation to
the beginning of the problem. It is likely that the passage
of time makes it harder for patients to recall dates and
events that occurred prior to their admission, especially
as medical consultations might blend with in-hospital
consultations. This process could be even more challen-
ging for patients who have already started chemotherapy
(as was the case of most of our retest participants) be-
cause common secondary effects of chemotherapy in-
clude memory loss and difficulty concentrating [42].
These findings suggest that to minimise recall bias when
assessing delay, the patients should be interviewed as
early as possible, as has been suggested in previous stud-
ies [12,31].
Recall bias also seems to explain the poor external
consistency scores of some other questionnaire items,
including symptoms present when the patient first
arrived at INCAN, the diagnosis offered by the first doc-
tor consulted, the tests requested by this first doctor,
and the time that passed from identification of the prob-
lem until the patient told someone about the problem.
The remaining poor test-retest consistency scores could
be explained by changes in these items over time. The
first interview took place before the cancer diagnosis,
while the second interview took place after treatment
had begun. Items with poor consistency that could have
changed over time include use of alternative medicine,
knowing a person with cancer and knowledge of recom-
mended breast cancer screening practices.
In regard to the length of the intervals reported in our
findings, the median total interval was very prolonged
for our study population (median: 234.5 days) and the
main delays seem to be presenting within the provider
interval (median: 151 days). This is similar to findings of
studies that have been done in other Latin American
countries. For example, another Mexican study that was
done with a small sample of breast cancer patients
(n=32) with public health insurance reported a mean
total interval of 8.4 months [43]. A Colombian study of
1106 breast cancer patient files reported a median time
from the first medical consultation to diagnosis confirm-
ation (diagnosis interval) of 91 days [44] and a Brazilian
study with 104 patients reported a median diagnosis
interval of 6.5 months [45].Another matter that we would like to briefly discuss is
related to whether a self-complete tool could have provided
a more objective way of administering the questionnaire.
Such a tool could certainly reduce inter-observer variability
and response bias [30]. It has been shown, however, that
self-complete tools are difficult for undereducated popula-
tions (like our study population) to use [36,37]. This
strategy would have most likely yielded a high rate of in-
complete and inadequately filled-out questionnaires.
One limitation of our study is that external consistency
measures are not available for some items because these
items were identified as relevant only after the second
pilot study. Because these items are “patient perceptions
of barriers within the provider interval”, we hypothesise
that they are likely to have reliabilities similar to those
found for “perceptions of barriers within the patient inter-
val” (moderate; between 0.4 and 0.75).
One more limitation was the impossibility of con-
structing scales for the social network of support for
medical attention and health service utilisation. Another
limitation was the lack of correlation between most of
the social network items and the delay intervals. Never-
theless, we think that it is still premature to decide
which of these items should be kept or discarded before
the instrument is tested in a greater and more heteroge-
neous sample with higher levels of education, formal
employment and higher socioeconomic status.
A disadvantage of the instrument is that its application
is time-consuming, especially for older participants and
those with low levels of education. On the other hand, it
has high acceptability for patients, especially if it is
administered when they first arrive at the hospital, be-
fore they see the breast specialist.
Conclusions
On the basis of our analyses, we conclude that the
Breast Cancer Delay Questionnaire is a valid, reliable
and sensitive measure of the total, patient and provider
intervals and the predisposing factors of delay in unin-
sured breast cancer patients treated at a public institu-
tion in Mexico. We think it could be useful in other
settings, with similar populations, although it would
have to be contextually adapted.
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